Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281562 · ClinicalTrials.gov registry record · Phase 2
Immunonutrition for Diabetic Foot Ulcers
A Phase 2 study, sponsored by Prisma Health-Midlands.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05281562 is a Phase 2 study that was terminated before completion, run by Prisma Health-Midlands. The registered enrollment target is 1 participants.
The verdict
NCT05281562, a Phase 2 study, was terminated before completion, sponsored by Prisma Health-Midlands.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Diabetes-induced peripheral neuropathy can lead to the development of diabetic foot ulcers (DFUs), which can have a devastating effect on patients' lives and can lead to life threatening infection, amputations, and even death. Conventional treatment of DFUs are time consuming, burdensome, costly, and often do not treat the root cause of the problem. Even with proper care, ulcers can take a significantly longer time to heal in diabetic patients due to the altered physiology which does not allow for the proper nutrients and healing factors to mobilize to the site of injury, leaving these ulcers with a poor chance of healing and at high risk for infection and possible amputation. Supplemental immunonutrition therapy may offer a viable, low cost, rapidly scalable, and widely available approach to enhance the body's ability to heal itself. This prospective, randomized pilot study will evaluate the effect of a 6-week daily oral course of a specific combination of immunonutrients, L-Arginine, Omega-3 fatty acids, and Vitamin C, on wound healing in diabetic patients with chronic lower extremity ulcers compared to traditional standard of care. The deliverables of this clinical project will serve to advance a cost-effective added strategy to address a significant unmet clinical need in treatment for the diabetic patient population. Study outcomes will lay the foundation for a multi-site clinical trial to establish the efficacy and cost-effectiveness of this strategy across the health care system.
Interventions
- DRUG Vitamin C
- DRUG Lovaza
- DRUG L-Arginine Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05281562
The ClinicalTrials.gov registry entry for NCT05281562 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Midlands, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vitamin C is the first listed.
NCT05281562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05281562 about?
NCT05281562 is a clinical study titled "Immunonutrition for Diabetic Foot Ulcers". Diabetes-induced peripheral neuropathy can lead to the development of diabetic foot ulcers (DFUs), which can have a devastating effect on patients' lives and can lead to life threatening infection, amputations, and even death. Conventional treatment of DFUs are time consuming, burdensome, costly, an...
What is the current status of trial NCT05281562?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-02-08. Estimated completion is 2023-03-20.
What interventions are being tested in trial NCT05281562?
The interventions under investigation include: Vitamin C (DRUG), Lovaza (DRUG), L-Arginine Powder (DRUG).
Who is sponsoring clinical trial NCT05281562?
This trial is sponsored by Prisma Health-Midlands, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.